Adult Pneumococcal Disease: A Neglected Crisis?
20 Frequently Asked Questions
Release Date: Monday, April 18, 2011
Credit Expiration Date: Tuesday, April 17, 2012
Physician CME: 2.0
Pharmacists CPE: 2.0
Practice Gap and Educational Need
Pneumococcal disease remains a leading cause of infectious disease in
adults. Serious manifestations, such as pneumonia and bacteremia, are
associated with significant morbidity and mortality, and frequent hospitalization
places a heavy financial burden on the healthcare system. Additionally, widespread
resistance to commonly-used antimicrobials challenges clinicians in selecting
Prevention and management tactics can help address the challenge associated with
pneumococcal disease. Early appropriate antimicrobial therapy is essential for optimal
clinical outcomes. Furthermore, pneumococcal vaccination protects at-risk
adults. However, despite recommendations from the Centers for Disease
Control and Prevention, a significant percentage of at-risk adults is not vaccinated
and remains vulnerable to pneumococcal infections. Healthcare professionals must
recognize the impact of pneumococcal disease and advance their efforts in
preventing and managing pneumococcal infections. As part of a multidisciplinary
team, clinical pharmacists can take a leading role.
"Adult Pneumococcal Disease: A Neglected Crisis", an educational initiative
comprising a CME/CPE symposium and its simulcast, webcast on-demand, and now
this monograph, aims to assist healthcare professionals in their efforts to
prevent pneumococcal disease.
This activity was planned to meet the needs of pharmacists, physicians, and
other healthcare professionals who are interested in learning more about
prevention and management of pneumococcal disease.
Healthcare professionals participating in this educational activity will be able at its conclusion to:
- Recognize the healthcare burden of pneumococcal disease in adults
- Utilize guidelines to identify adults who would benefit from pneumococcal vaccination
- Explain the role of pharmacists in preventing pneumococcal disease in adults
This CME/CPE monograph provides evidence-based answers to frequently asked
questions pertaining to pneumococcal disease management and prevention. As a
user-friendly reference guide, it aims to promote partnership among
physicians, pharmacists, and other healthcare professionals to maximize
the use of adult pneumococcal vaccines for all at-risk adults.
Thomas M. File, Jr., MD, MSc, MACP, FIDSA, FCCP
Professor of Internal Medicine
Head, Infectious Disease Section
Northeastern Ohio Universities Colleges of Medicine
Chief, Infectious Disease Service
Director, HIV Research
Summa Health System
David S. Burgess, PharmD, FCCP
Clinical Professor of Pharmacy and Medicine
Center for Advancement of Research and Education in Infectious Disease
University of Texas at Austin
University of Texas Health Science Center at San Antonio
San Antonio, Texas
This activity has been planned and implemented in accordance with the Essential Areas and
Policies of the Accreditation Council for Continuing Medical Education. National Foundation
for Infectious Diseases designates this enduring material for a maximum of 2.0 AMA PRA
Category 1 Credits™. Physicians should claim only the credit commensurate with the extent
of their participation in the activity.
University of Illinois at Chicago (UIC) is accredited by the Accreditation Council for Pharmacy
Education as a provider of continuing pharmacy education. UIC has assigned 2.0 contact
hours (0.2 CEUs) of continuing pharmacy education credits for participating in this
activity. Participants must complete the entire activity and submit the Post Test and Evaluation
Form in order to receive continuing pharmacy education credit.
ACPE Universal Activity Number: 016-999-11-033-H01-P
Type of Activity: Knowledge-based
Method of Participation and Instruction for Credit
Physicians: Documentation of credit will be mailed within 6 weeks of receipt of the
completed Post Test and Evaluation Form.
- Review the entire CME/CPE information including target
audience, learning objectives, and disclosures.
- Review the entire Monograph.
- Complete the Post Test and Evaluation Form. Please note that to receive credit you must have a score of at least 80%.
- Mail the completed Post Test and Evaluation Form
to Vemco MedEd, 245 US Highway 22, Suite 304, Bridgewater, NJ 08807 or fax to (908) 235-4222.
Pharmacists: You will be notified via email within 6 weeks of receipt of the
completed Post Test and Evaluation Form when your statement of pharmacy credit
is available. You may print your certificate of pharmacy credit by logging onto
the website at
Disclosure of Conflicts of Interest
National Foundation for Infectious Diseases, University of Illinois at Chicago, and Vemco MedEd
require faculty, planners, and others who are in a position to control the content of continuing
education activities to disclose to the audience any real or apparent conflict of interest
related to the activity. All identified conflicts of interest are reviewed and resolved to
ensure fair balance, objectivity, and scientific rigor in all activities. The faculty is
further required to disclose discussion of off-label uses in their presentations.
Disclosures: Guest Editors
Thomas M. File, Jr., MD has received research funding from Cempra, Pfizer, Boehringer
Ingelheim, Gilead, Tibotec. He serves as a consultant for Bayer, Cempra, Cerexa/Forest,
Merck, Nabriva, Pfizer, Rib-X, Tetraphase.
David S. Burgess, PharmD has no relevant financial relationships to disclose.
Disclosure: Planning Committee
Len Novick (NFID) owns stock, stock options or bonds from Cubist, Novavax, Pfizer, and ViroPharma.
Susan J. Rehm, MD (NFID) serves as an advisor or consultant for Pfizer and Cubist. She
serves as a speaker or member of a speakers’ bureau for Cubist and Roche and has received
research/grant support from Cubist.
All other employees of the National Foundation for Infectious Diseases, University of
Illinois at Chicago, and Vemco MedEd have no relevant financial relationships to disclose.
Disclosure of Off-label Use
During this activity, the following off-label use of a vaccine is discussed: 13-valent
pneumococcal conjugate vaccine for prevention of pneumococcal disease in adults.
This activity is cosponsored by
This activity is supported by an unrestricted educational grant to the National Foundation for
Infectious Diseases from Pfizer, Inc.
There is no fee to participate in this activity.
Microsoft Internet Explorer, Mozilla Firefox, Apple Safari or Google Chrome
Note: Please disable any "pop-up blocker" features.
Adobe® Flash® Player version 10 or above to view the presentations (If you do not have Adobe® Flash® Player, you can
download it for free from get.adobe.com/flashplayer)
Adobe Acrobat Reader version 7 or above to view PDF files (If you do not have Acrobat Reader, you can download it
for free from get.adobe.com/reader)
Cable, DSL, or better of at least 300 kbps
Please e-mail any questions or concerns to email@example.com.
The opinions expressed in this educational activity are those of the faculty and do not reflect
the views of National Foundation for Infectious Diseases, University of Illinois at Chicago, and
Vemco MedEd. This educational activity may discuss off-label and/or investigational uses and
dosages for therapeutic products/procedures that have not been approved by the United States
Food and Drug Administration (FDA). National Foundation for Infectious Diseases, University
of Illinois at Chicago, and Vemco MedEd do not recommend the use of any product/procedure
outside of the labeled indications. A qualified healthcare professional should be consulted
before using any therapeutic product/procedure discussed. Clinicians should verify all
information and data before treating patients or employing any therapies described in this
continuing education activity. Please refer to the prescribing information for each product/procedure
for approved indication, contraindications, and warnings.
For questions regarding the accreditation of this activity, please contact NFID at (301) 656-0003
extension 12 or UIC at (866) 742-7623.
By clicking on the following icons, I acknowledge that I have read the
entire CME/CE information.